Tricuspid Valve Disease
0
Pipeline Programs
1
Companies
2
Clinical Trials
2 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
CorVivoGA - Roswell
2 programsCorMatrix Cor TRICUSPID ECM ValveN/A1 trial
Tricuspid valve replacement with the Cor TRICUSPID ECM ValveN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2022
2023
2024
2025
2026
CorVivoTricuspid valve replacement with the Cor TRICUSPID ECM Valve
CorVivoCorMatrix Cor TRICUSPID ECM Valve
Clinical Trials (2)
Total enrollment: 170 patients across 2 trials
CorMatrix Cor TRICUSPID ECM Valve Replacement - Pivotal Study
Start: Aug 2022Est. completion: Dec 202692 patients
N/ARecruiting
CorMatrix Cor TRICUSPID ECM Valve Replacement Study
Start: Aug 2022Est. completion: Dec 202678 patients
N/ARecruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 actively recruiting trials targeting 170 patients
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.